46 results on '"Ozgenc F"'
Search Results
2. Outcome of pediatric liver transplant recipients in Turkey: Single center experience
- Author
-
Aydogdu, S., Arikan, C., Kilic, M., Ozgenc, F., Akman, S., Unal, F., Yagci, R. V., and Tokat, Y.
- Published
- 2005
3. Association between anti-endomysial antibody and total intestinal villous atrophy in children with coeliac disease
- Author
-
Ozgenc, F, Aksu, G, Aydogdu, S, Akman, S, Genel, F, Kutukculer, N, Alkanat, MB, and Vural Yagci, R
- Subjects
Practice ,Diagnosis ,Tests, problems and exercises ,Care and treatment ,Usage ,Analysis ,Physiological aspects ,Research ,Genetic aspects ,Health aspects ,Causes of ,Medical examination -- Practice -- Analysis -- Physiological aspects -- Usage -- Tests, problems and exercises -- Research -- Health aspects ,Atrophy -- Health aspects -- Causes of -- Genetic aspects -- Care and treatment -- Diagnosis -- Research ,Fluorescent antibody technique -- Usage -- Analysis -- Genetic aspects -- Physiological aspects -- Research -- Health aspects -- Tests, problems and exercises ,Diagnosis -- Analysis -- Tests, problems and exercises -- Usage -- Research -- Health aspects -- Physiological aspects ,Medical students -- Tests, problems and exercises -- Research -- Physiological aspects -- Analysis -- Health aspects -- Usage ,Sick children -- Health aspects -- Care and treatment -- Research -- Tests, problems and exercises -- Analysis -- Physiological aspects -- Usage ,Clinical medicine -- Research -- Analysis -- Physiological aspects -- Usage -- Tests, problems and exercises -- Health aspects ,Postdoctoral education -- Tests, problems and exercises -- Health aspects -- Analysis -- Usage -- Research -- Physiological aspects ,Histology -- Research -- Health aspects -- Tests, problems and exercises -- Usage -- Analysis -- Physiological aspects ,Antibodies -- Genetic aspects -- Physiological aspects -- Health aspects -- Research -- Tests, problems and exercises -- Usage -- Analysis ,Celiac disease -- Health aspects -- Diagnosis -- Care and treatment -- Genetic aspects -- Research ,Viral antibodies -- Genetic aspects -- Physiological aspects -- Health aspects -- Research -- Tests, problems and exercises -- Usage -- Analysis ,Physical diagnosis -- Practice -- Analysis -- Physiological aspects -- Usage -- Tests, problems and exercises -- Research -- Health aspects ,Periodic health examinations -- Practice -- Analysis -- Physiological aspects -- Usage -- Tests, problems and exercises -- Research -- Health aspects ,Immunofluorescence -- Usage -- Analysis -- Genetic aspects -- Physiological aspects -- Research -- Health aspects -- Tests, problems and exercises - Abstract
BACKGROUND: There is growing evidence to suggest that detection of anti-gliadin antibody (AGA) and anti-endomysial antibody (EmA) can serve as sensitive markers of the degree of histological abnormalities in patients [...]
- Published
- 2003
4. Early and Late Factors Impacting Patient and Graft Outcome in Pediatric Liver Transplantation: Summary of an ESPGHAN Monothematic Conference
- Author
-
Mclin, V, Allen, U, Boyer, O, Bucuvalas, J, Colledan, M, Cuturi, M, D'Antiga, L, Debray, D, Dezsofi, A, de Goyet, J, Dhawan, A, Durmaz, O, Falk, C, Feng, S, Fischler, B, Franchi-Abella, S, Frauca, E, Ganschow, R, Gottschalk, S, Hadzic, N, Hierro, L, Horslen, S, Hubscher, S, Karam, V, Kelly, D, Maecker-Kolhoff, B, Mazariegos, G, Mckiernan, P, Melk, A, Nobili, V, Ozgenc, F, Reding, R, Sciveres, M, Sharif, K, Socha, P, Toso, C, Vajro, P, Verma, A, Wildhaber, B, Baumann, U, Mclin VA, Allen U, Boyer O, Bucuvalas J, Colledan M, Cuturi MC, d'Antiga L, Debray D, Dezsofi A, de Goyet JD, Dhawan A, Durmaz O, Falk C, Feng S, Fischler B, Franchi-Abella S, Frauca E, Ganschow R, Gottschalk S, Hadzic N, Hierro L, Horslen S, Hubscher S, Karam V, Kelly D, Maecker-Kolhoff B, Mazariegos G, McKiernan P, Melk A, Nobili V, Ozgenc F, Reding R, Sciveres M, Sharif K, Socha P, Toso C, Vajro P, Verma A, Wildhaber BE, Baumann U, Mclin, V, Allen, U, Boyer, O, Bucuvalas, J, Colledan, M, Cuturi, M, D'Antiga, L, Debray, D, Dezsofi, A, de Goyet, J, Dhawan, A, Durmaz, O, Falk, C, Feng, S, Fischler, B, Franchi-Abella, S, Frauca, E, Ganschow, R, Gottschalk, S, Hadzic, N, Hierro, L, Horslen, S, Hubscher, S, Karam, V, Kelly, D, Maecker-Kolhoff, B, Mazariegos, G, Mckiernan, P, Melk, A, Nobili, V, Ozgenc, F, Reding, R, Sciveres, M, Sharif, K, Socha, P, Toso, C, Vajro, P, Verma, A, Wildhaber, B, Baumann, U, Mclin VA, Allen U, Boyer O, Bucuvalas J, Colledan M, Cuturi MC, d'Antiga L, Debray D, Dezsofi A, de Goyet JD, Dhawan A, Durmaz O, Falk C, Feng S, Fischler B, Franchi-Abella S, Frauca E, Ganschow R, Gottschalk S, Hadzic N, Hierro L, Horslen S, Hubscher S, Karam V, Kelly D, Maecker-Kolhoff B, Mazariegos G, McKiernan P, Melk A, Nobili V, Ozgenc F, Reding R, Sciveres M, Sharif K, Socha P, Toso C, Vajro P, Verma A, Wildhaber BE, and Baumann U
- Abstract
As pediatric liver transplantation comes of age, experts gathered to discuss current paradigms and define gaps in knowledge warranting research to further improve patient and graft outcomes. Identified areas ripe for collaborative research include understanding the molecular and cellular mechanisms of tolerance and the role of donor-specific antibodies, considering ways to expand donor pool, minimizing long-term side effects of immunosuppression, and fine-tuning surgical techniques to minimize biliary and vascular complications. Copyright © 2017 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
- Published
- 2017
5. Stress magnet ingestion in three children: Endoscopist perspective
- Author
-
Ozgenc F., Yuksekkaya H., Erdemir G., Ecevit C., Yagci R., and Ege Üniversitesi
- Subjects
foreign body ingestion ,digestive, oral, and skin physiology ,equipment and supplies ,human activities ,magnet - Abstract
The widespread use of magnets in toy industry has resulted in increased reports of magnet ingestions and related complications. Ensconcing within plastic covers and manufacturing larger pieces have been forwarded to avoid ingestion. We report 3 cases of magnet ingestion called "stress magnets" which are large to pass the gastric outlet. Endoscopic retrieval of single and double magnets from the stomach is described, and magnet related health hazard as well as the procedure related adversities is discussed. © 2012 Akadémiai Kiadó, Budapest.
- Published
- 2012
6. Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection
- Author
-
Dikici, B, Kalayci, AG, Ozgenc, F, Bosnak, M, Davutoglu, M, Ece, A, Haspolat, K, and Ondokuz Mayıs Üniversitesi
- Subjects
therapy ,children ,vaccine ,chronic infection ,hepatitis B virus ,digestive system diseases ,immunotolerance - Abstract
ECE, AYDIN/0000-0001-9130-2431; Ece, Aydin/0000-0001-6764-8336; dikici, bunyamin/0000-0001-7572-6525 WOS: 000182327600008 PubMed: 12690275 Aim. Hepatitis B virus (HBV) infection is a major global health concern and is the most common cause of chronic liver disease worldwide. Our aim was to investigate the efficacy of specific HBV vaccination as active immunotherapy in treating chronic hepatitis B (CHB) infection during the immunotolerant phase of children with normal aminotransferase values and high viral load. Materials and methods. Seventy-four patients never vaccinated before were randomly and prospectively recruited into two groups. Group 1 included 43 patients vaccinated with three standard injections of the GenHevac B vaccine at 30-day intervals. Group 2 contained 31 patients who did not receive any medication or vaccination (control group). Postvaccination serologic and virologic evaluation was performed 6 months after the first injection and at the end of the 12th month. Response to therapy was defined as loss of HBV DNA in serum and hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg), development of hepatitis B e antibody (anti-HBe). Results. The mean baseline alanine aminotransferase (ALT) value in Group 1 was 33.0 +/- 9.6 IU/I, 34.6 +/- 13.9 IU/I at 6 months after first injection and 34.3 +/- 17.1 IU/I at end of 12 months (P > 0.05). In Group I the HBV DNA load at the start of immunization was 3571 +/- 1292 pg/ml; this value was 3220 +/- 1217 pg/ml at the 6th month and 2931 +/- 1292 pg/ml at the 12th month (P > 0.05). In Group 2 the mean ALT values at the beginning of therapy and at the 6th and 12th months were 32.6 +/- 7.8, 32.3 +/- 8.0 and 30.3 +/- 7.3 IU/I, respectively (P > 0.05), and the mean viral load HBV DNA values were 3909 1378, 3546 869 and 3106 +/- 718 pg/ml, respectively (P > 0.05). There was no statistically significant difference between Group 1 and Group 2 at the end of the 6th and 12th months in the mean ALT values and mean viral load of HBV DNA (P > 0.05). Except for one patient in each group, hepatitis B surface antigen and HBeAg clearance or hepatitis B surface antibody and anti-HBe seroconversion were not observed during follow-up (P > 0.05). Conclusion. In this multicentered study comparison of vaccinated and unvaccinated groups of immunotolerant children with CHB infection showed no difference in the clearance of HBV DNA or seroconversion from HBeAg to anti-HBe. Different immunization protocols should be considered for future investigations in the inununo-tolerant phase of children with CHB infection.
- Published
- 2003
7. Antigliadin antibodies and antiendomysial antibodies in Down syndrome children
- Author
-
Cogulu, O, Özkınay, FF, Gunduz, C, Cankaya, T, Aydogdu, S, Ozgenc, F, Kutukculer, N, Özkınay, C, and Ege Üniversitesi
- Abstract
European-Society-of-Human-Genetics European Human Genetics Conference in Conjuction With European Meeting on Psychosocial Aspects of Genetics -- MAY 25-28, 2002 -- STRASBOURG, FRANCE, WOS: 000187166100325, European Soc Human Genet
- Published
- 2002
8. Inflammatory myofibroblastic tumor of small bowel wall in childhood
- Author
-
Demirkan, NC, Akalin, T, Yilmaz, F, Ozgenc, F, Ozcan, C, Alkanat, MB, and Aydogdu, S
- Subjects
inflammatory myofibroblastic tumor ,inflammatory pseudotumor ,small ,cardiovascular system ,cardiovascular diseases ,bowel - Abstract
Benign intestinal tumors are rare in children, however we describe an inflammatory myofibroblastic tumor (IMT) of the jejunum in a 2-year-old girl who presented with an intestinal obstruction. During laparotomy, an annular mass around the jejunum was resected, from which a histological diagnosis of IMT was made. A review of the literature for this rare entity emphasizes the importance of histological confirmation of its benign nature. Because of the risk of local recurrence, IMT cases should have a long-term follow up.
- Published
- 2001
9. Association between anti-endomysial antibody and total intestinal villous atrophy in children with coeliac disease.
- Author
-
Ozgenc F, Aksu G, Aydogdu S, Akman S, Genel F, Kutukculer N, Alkanat M, Vural Yagci R, Ozgenc F, Aksu G, Aydogdu S, Akman S, Genel F, Kutukculer N, Alkanat M, and Vural Yagci R
- Abstract
BACKGROUND: There is growing evidence to suggest that detection of anti-gliadin antibody (AGA) and anti-endomysial antibody (EmA) can serve as sensitive markers of the degree of histological abnormalities in patients with coeliac disease. AIM: To evaluate the association between the presence of AGA and EmA and villous atrophy in intestinal biopsies of children with suspected coeliac disease. SETTINGS AND DESIGN: Intestinal samples of 46 children with failure to thrive, chronic diarrhoea, malabsorption and short stature with either AGA and/or EmA positivity were evaluated, retrospectively. The diagnosis of coeliac disease was based on ESPGHAN criteria. METHODS AND MATERIAL: Patients with total villous atrophy who fulfilled the ESPGHAN criteria for the diagnosis of coeliac disease were diagnosed to have coeliac disease. Nine patients without villous atrophy were taken as negative controls for this study. AGA-IgA was measured both by immunoflourescence (IF) and ELISA and EmA-IgA by IF while patients were on normal diet. Relationship between autoantibody positivity and intestinal total villous atrophy was evaluated. RESULTS: Overall positivity for AGA IgA was 85% (39/46) by IF+ELISA and EmA positivity was 85% (39/46) by IF within the study group. Histological examination revealed total villous atrophy with lymphocyte infiltration and crypt hyperplasia in 37 (80%) patients. AGA IgA was positive in 14 (38%) and 31 (84%) of these children by ELISA and IF, respectively. EmA positivity was detected in 35/37 (95%) cases with atrophy and 4/9 (44%) without atrophy (p=0.002). Thirty out of 37 (81%) patients with villous atrophy had both AGA IgA (IF) and EmA positivity (p=0.186). All of the sixteen patients that had both positive AGA IgA (ELISA+IF) and EmA had total villous atrophy (p=0.037). CONCLUSION: A significant association between total villous atrophy and EmA positivity has been documented in this study
- Published
- 2003
10. Ventral abdominal herniation through PEG site in a child with cystic fibrosis
- Author
-
Ozutemiz, O., primary, Oruc, N., additional, Tekin, F., additional, Ozgenc, F., additional, and Yagci, R., additional
- Published
- 2007
- Full Text
- View/download PDF
11. The influence of marginal zinc deficient diet on post-vaccination immune response against hepatitis B in rats
- Author
-
OZGENC, F, primary, AKSU, G, additional, KIRKPINAR, F, additional, ALTUGLU, I, additional, COKER, I, additional, KUTUKCULER, N, additional, and YAGCI, R, additional
- Published
- 2006
- Full Text
- View/download PDF
12. Hepatocellular carcinoma in children and effect of living‐donor liver transplantation on outcome
- Author
-
Arikan, C., primary, Kilic, M., additional, Nart, D., additional, Ozgenc, F., additional, Ozkan, T., additional, Tokat, Y., additional, Yagci, R. V., additional, and Aydogdu, S., additional
- Published
- 2005
- Full Text
- View/download PDF
13. Comparison of Sequence Analysis and INNO-LiPA HBV DR Line Probe Assay in Patients with Chronic Hepatitis B
- Author
-
Sertoz, R.Y., primary, Erensoy, S., additional, Pas, S., additional, Akarca, U.S., additional, Ozgenc, F., additional, Yamazhan, T., additional, Ozacar, T., additional, and Niesters, H.G.M., additional
- Published
- 2005
- Full Text
- View/download PDF
14. THE POSITIVE ASSOCIATION OF MIF GENE ???173 G/C POLYMORPHISM WITH BILIARY ATRESIA IN TURKISH PATIENTS
- Author
-
Arikan, C, primary, Berdeli, A, additional, Ozgenc, F, additional, Aydogdu, S, additional, and Yagci, R, additional
- Published
- 2005
- Full Text
- View/download PDF
15. P0233 IMPACT OF LIVER TRANSPLANTATION ON RATE CORRECTED Q‐T INTERVAL IN PATIENTS WITH CHRONIC LIVER DISEASE
- Author
-
Arikan, C., primary, Tumgor, G., additional, Levent, E., additional, Ozgenc, F., additional, Akman, S. A., additional, Kilic, M., additional, Yagci, R. V., additional, and Aydogdu, S., additional
- Published
- 2004
- Full Text
- View/download PDF
16. P0341 LONG‐TERM LAMIVUDINE THERAPY IN CHRONIC HBV INFECTED CHILDREN
- Author
-
Ozgenc, F., primary, Aydogdu, S., additional, Altuglu, Ý., additional, Nart, D., additional, Tumgor, G., additional, Aksit, S., additional, and Yagci, R. V., additional
- Published
- 2004
- Full Text
- View/download PDF
17. P0324 DNA CLEARENCE AS AN EARLY PREDILICTION OF RESPONSE IN CHRONIC HEPATITIS B INFECTION DURING THERAPY
- Author
-
Ozgenc, F., primary, Dikici, B., additional, Targan, S., additional, Kalayci, A. A. G., additional, Doganci, T., additional, Aydogdu, S., additional, and Yagci, R. V., additional
- Published
- 2004
- Full Text
- View/download PDF
18. P0248 MASSIVE ASCITES AFTER PEDIATRIC LIVER TRANSPLANTATION: THE ROLE OF NUTRITION
- Author
-
Aydogdu, S., primary, Arikan, C., additional, Parildar, M., additional, Ozgenc, F., additional, Kilic, M., additional, and Yagci, R. V., additional
- Published
- 2004
- Full Text
- View/download PDF
19. P0334 TLR4 GENE MUTATION IN HOST DEFENCE AGAINST HEPATITIS B VIRUS
- Author
-
Ozgenc, F., primary, Berdeli, A., additional, Arikan, C., additional, Aydogdu, S., additional, and Yagci, R. V., additional
- Published
- 2004
- Full Text
- View/download PDF
20. Current therapeutic approaches in childhood chronic hepatitis B infection
- Author
-
Dikici, B., primary, Ozgenc, F., additional, Kalayci, A., additional, Targan, S., additional, Ozkan, T., additional, Selimoglu, A., additional, Doganci, T., additional, Kansu, A., additional, Tosun, S., additional, Arslan, N., additional, Kasirga, E., additional, Bosnak, M., additional, Ece, A., additional, Buyukgebiz, B., additional, Aydogdu, S., additional, Girgin, N., additional, and Yagci, R.V., additional
- Published
- 2003
- Full Text
- View/download PDF
21. Compound Heterozygote of a Novel Missense Mutation (p.K402T) and a Double Missense Mutation (p.[G71R;Y486D]) in Type II Crigler-Najjar Syndrome.
- Author
-
Maruo Y, Ozgenc F, Mimura Y, Ota Y, Matsui K, Takahashi H, Mori A, Taga T, Takano T, Sato H, and Takeuchi Y
- Published
- 2011
- Full Text
- View/download PDF
22. Immune status and autoantibody formation in children with chronic hepatitis B infection
- Author
-
Unal, F., Genel, F., Ozgenc, F., Guzide Aksu, Aydogdu, S., Kutukculer, N., and Yagci, R. V.
- Subjects
Male ,Hepatitis B, Chronic ,Adolescent ,Child, Preschool ,Immune System ,Antibody Formation ,Humans ,Infant ,Female ,Child ,Autoantibodies - Abstract
The hepatitis B virus (HBV) causes a wide spectrum of disease which ranges from acute hepatitis to liver cirrhosis. Patients who fail to mount a vigorous immune response in acute HBV develop chronic infection. Therefore, the aim of the study was to determine the cellular and humoral immune parameters of the patients with chronic HBV and to evaluate the prevalence of autoantibodies before the beginning of immunomodulator and antiviral therapy.In this comparative study, serum immunoglobulins, IgG subclasses, secretory IgA, serum complement components, lymphocyte subsets and CD11a, CD18, CD54 molecules on lymphocytes were determined in 44 hospitalized patients of chronic HBV infection and 20 cases of healthy control subjects.Significant increase in IgG and significant decrease in the complement C4 were observed. The mean percentage of CD3+ lymphocytes, reflecting the percentage of total T cells was significantly higher in the patient group due to the increase of CD8+ lymphocytes. The mean percentage of CD19+ B lymphocytes was lower in the patient group secondary to the increase of their total T cells. No significant difference was found in cell surface adhesion molecules between patient and control groups. The percentage of antinuclear antibody positivity was 18.2%.Our data show that ANA formation is part of the natural course of chronic HBV infection and this value may reflect the tendency to autoimmune diseases and the importance of clinical follow-up. The abnormalities observed in immunological parameters may reflect the role of the cellular and humoral immune system in pathogenesis.
23. THE POSITIVE ASSOCIATION OF MIF GENE −173 G/C POLYMORPHISM WITH BILIARY ATRESIA IN TURKISH PATIENTS
- Author
-
Arikan, C, Berdeli, A, Ozgenc, F, Aydogdu, S, and Yagci, R
- Published
- 2005
- Full Text
- View/download PDF
24. EFFICIENCY AND SAFETY OF ESOPHAGEAL BAND LIGATION AND SCLEROTHERAPY IN CHILDREN WITH ESOPHAGEAL VARICES.
- Author
-
Aydogdu, S, Tumgor, G, Yuksekkaya, H.A, Cakir, M, Arikan, C, Baran, M, Ozgenc, F, and Yagci, R.V
- Published
- 2006
- Full Text
- View/download PDF
25. Early and Late Factors Impacting Patient and Graft Outcome in Pediatric Liver Transplantation: Summary of an ESPGHAN Monothematic Conference
- Author
-
Stefan G. Hubscher, Sandy Feng, Vincent Karam, Stephen Gottschalk, Anil Dhawan, Pietro Vajro, Raymond Reding, Dominique Debray, Nedim Hadzic, Valérie A. McLin, Valerio Nobili, Christian Toso, Khalid Sharif, Ozlem Durmaz, Stéphanie Franchi-Abella, Deirdre Kelly, Michele Colledan, Funda Ozgenc, Ulrich Baumann, Patrick J. McKiernan, Rainer Ganschow, Barbara E. Wildhaber, Anita Verma, Lorenzo D'Antiga, Loreto Hierro, George V. Mazariegos, Marco Sciveres, John C. Bucuvalas, Jean de Ville de Goyet, Christine S. Falk, Simon Horslen, Anette Melk, Maria-Cristina Cuturi, Antal Dezsofi, Olivia Boyer, Upton Allen, Esteban Frauca, Britta Maecker-Kolhoff, Piotr Socha, Björn Fischler, Mclin, V, Allen, U, Boyer, O, Bucuvalas, J, Colledan, M, Cuturi, M, D'Antiga, L, Debray, D, Dezsofi, A, de Goyet, J, Dhawan, A, Durmaz, O, Falk, C, Feng, S, Fischler, B, Franchi-Abella, S, Frauca, E, Ganschow, R, Gottschalk, S, Hadzic, N, Hierro, L, Horslen, S, Hubscher, S, Karam, V, Kelly, D, Maecker-Kolhoff, B, Mazariegos, G, Mckiernan, P, Melk, A, Nobili, V, Ozgenc, F, Reding, R, Sciveres, M, Sharif, K, Socha, P, Toso, C, Vajro, P, Verma, A, Wildhaber, B, and Baumann, U
- Subjects
Graft Rejection ,medicine.medical_specialty ,Tissue and Organ Procurement ,research goal ,medicine.medical_treatment ,complication ,030230 surgery ,Liver transplantation ,Pediatrics ,Drug Administration Schedule ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Outcome Assessment, Health Care ,Humans ,Medicine ,Child ,Intensive care medicine ,Donor pool ,Settore MED/38 - Pediatria Generale e Specialistica ,ddc:618 ,tolerance ,liver transplantation ,business.industry ,Graft Survival ,Gastroenterology ,Immunosuppression ,pediatric ,Pediatrics, Perinatology and Child Health ,Quality of Life ,030211 gastroenterology & hepatology ,business ,Immunosuppressive Agents - Abstract
As pediatric liver transplantation comes of age, experts gathered to discuss current paradigms and define gaps in knowledge warranting research to further improve patient and graft outcomes. Identified areas ripe for collaborative research include understanding the molecular and cellular mechanisms of tolerance and the role of donor-specific antibodies, considering ways to expand donor pool, minimizing long-term side effects of immunosuppression, and fine-tuning surgical techniques to minimize biliary and vascular complications. Copyright © 2017 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
- Published
- 2017
- Full Text
- View/download PDF
26. Gastroesophageal reflux with children requiring adenotonsillectomy.
- Author
-
Tumgor G, Midilli R, Doganavsargil B, Ozgenc F, Arikan C, Kirazli T, and Yagci RV
- Subjects
- Adenoids pathology, Adenoids surgery, Adolescent, Case-Control Studies, Child, Child, Preschool, Esophageal pH Monitoring, Esophagitis, Peptic diagnosis, Female, Gastroesophageal Reflux diagnosis, Humans, Hypertrophy surgery, Laryngopharyngeal Reflux, Laryngoscopy, Male, Palatine Tonsil pathology, Palatine Tonsil surgery, Symptom Assessment, Adenoidectomy, Gastroesophageal Reflux epidemiology, Tonsillectomy
- Abstract
Background: Our aim is to determine the incidence of reflux in children older than 3 years requiring adenotonsillectomy and relationship between GER and diagnostic tests., Methods: Forty-four patients, who were listed for adenoidectomy/tonsillectomy at Pediatric Ear Nose Throat department due to severe hypertrophy, were evaluated for accompanying GER (Group 1). GER was diagnosed as having at least one positive GER test result (including esophagitis or pH monitoring). Twenty children without reflux symptoms were used as healthy control group (Group 2) and LPR was held., Results: Reflux was detected in 32 children requiring adenotonsillectomy (72.7%). LPR score was negative in all patients in Group 2. There was no correlation between pH monitoring and histopathological evaluation of esophagus. There was a correlation between the LPR score and histological esophagitis in the proximal esophagus., Conclusions: GER was high in patients with adenotonsillary hypertrophy. LPR score and the history of patients are as effective as invasive techniques like pH monitorization and endoscopy in determining GER disease.
- Published
- 2021
- Full Text
- View/download PDF
27. Familial Mediterranean Fever Mutation Analysis in Pediatric Patients With İnflammatory Bowel Disease: A Multicenter Study.
- Author
-
Urgancı N, Ozgenc F, Kuloğlu Z, Yüksekkaya H, Sarı S, Erkan T, Önal Z, Çaltepe G, Akçam M, Arslan D, Arslan N, Artan R, Aydoğan A, Balamtekin N, Baran M, Baysoy G, Çakır M, Dalgıç B, Doğan Y, Durmaz Ö, Ecevıt Ç, Eren M, Gökçe S, Gülerman F, Gürakan F, Hızlı S, Işık I, Kalaycı AG, Kansu A, Kutlu T, Karabiber H, Kasırga E, Kutluk G, Özbay Hoşnut F, Özen H, Özkan T, Öztürk Y, Bekem Soylu Ö, Tutar E, Tümgör G, Ünal F, Ugraş M, Üstündağ G, Yaman A, and Study Group TI
- Subjects
- Adolescent, Child, Colitis, Ulcerative epidemiology, Colitis, Ulcerative genetics, Crohn Disease epidemiology, Crohn Disease genetics, Humans, Familial Mediterranean Fever genetics, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases genetics, Mutation
- Abstract
Background: The aim of the study was to evaluate familial Mediterranean fever (FMF) mutation analysis in pediatric patients with inflammatory bowel disease (IBD). The relation between MEFV mutations and chronic inflammatory diseases has been reported previously., Methods: Children with IBD (334 ulcerative colitis (UC), 224 Crohn's disease (CD), 39 indeterminate colitis (IC)) were tested for FMF mutations in this multicenter study. The distribution of mutations according to disease type, histopathological findings, and disease activity indexes was determined., Results: A total of 597 children (mean age: 10.8 ± 4.6 years, M/F: 1.05) with IBD were included in the study. In this study, 41.9% of the patients had FMF mutations. E148Q was the most common mutation in UC and CD, and M694V in IC (30.5%, 34.5%, 47.1%, respectively). There was a significant difference in terms of endoscopic and histopathological findings according to mutation types (homozygous/ heterozygous) in patients with UC (P < .05). There was a statistically significant difference between colonoscopy findings in patients with or without mutations (P = .031, P = .045, respectively). The patients with UC who had mutations had lower Pediatric Ulcerative Colitis Activity Index (PUCAI) scores than the patients without mutations (P = .007)., Conclusion: Although FMF mutations are unrelated to CD patients, but observed in UC patients with low PUCAI scores, it was established that mutations do not have a high impact on inflammatory response and clinical outcome of the disease.
- Published
- 2021
- Full Text
- View/download PDF
28. Autoimmune hepatitis and long-term disease course in children in Turkey, a single-center experience.
- Author
-
Karakoyun M, Ecevit CO, Kilicoglu E, Aydogdu S, Yagci RV, and Ozgenc F
- Subjects
- Adolescent, Age of Onset, Autoantibodies blood, Biomarkers blood, Child, Drug Therapy, Combination, Female, Hepatitis, Autoimmune blood, Hepatitis, Autoimmune diagnosis, Hepatitis, Autoimmune immunology, Humans, Male, Recurrence, Remission Induction, Retrospective Studies, Time Factors, Treatment Outcome, Turkey, Azathioprine therapeutic use, Glucocorticoids therapeutic use, Hepatitis, Autoimmune drug therapy, Immunosuppressive Agents therapeutic use, Prednisolone therapeutic use
- Abstract
Introduction: The aim of this study is to determine clinic and laboratory features, treatment protocols, treatment responses, and long term follow-up of children with autoimmune hepatitis (AIH) in a region of Turkey followed at Ege University., Materials and Methods: The records of 47 children with AIH between 1998 and 2012 were retrospectively analyzed for clinical profiles, treatment response, relapse rate, and long-term side effects., Results: The median age of the children was 10±4.1 years (55.3% females). A total of 29 patients presented with chronic hepatitis (61.7%). According to the autoantibody profiles, 40 (85.1%) and seven (14.9%) cases were classified as type 1 and type 2, respectively. Presentation with acute hepatitis and chronic hepatitis was significantly higher in type 1 disease. Laboratory findings at presentation was found similar among races as well as AIH types (P>0.05). The prednisolone was used for remission induction in 37 patients; 86.4% (n: 32) achieved a complete response, 2.7% (n: 1) achieved a partial response, and four patients (10.8%) showed no response. Maintenance was attained by low-dose steroid plus thiopurine and relapse in steroid responders (n: 32) was 9.4% (n: 3) at 8, 12, and 48 months. A total of 36% (n: 24) had neither acute nor chronic treatment side effects. Bone marrow suppression was observed in five patients and hyperglycemia was observed in one patient (10.6 and 2.1%), respectively., Conclusion: AIH type 1 prevails in children in a region of Turkey during the second decade of life. Low-dose corticosteroids combined with azathioprine are found.
- Published
- 2016
- Full Text
- View/download PDF
29. C-reactive protein in children with active ulcerative colitis.
- Author
-
Ozgenc F, Ecevit CO, and Yagci RV
- Subjects
- Female, Humans, Male, C-Reactive Protein biosynthesis, Early Diagnosis, Inflammatory Bowel Diseases diagnosis
- Published
- 2012
- Full Text
- View/download PDF
30. Steroid response in moderate to severe pediatric ulcerative colitis: a single center's experience.
- Author
-
Cakir M, Ozgenc F, Yusekkaya HA, Ecevit CO, and Yagci RV
- Subjects
- Adolescent, Algorithms, Child, Child, Preschool, Colectomy, Colitis, Ulcerative diagnosis, Colitis, Ulcerative drug therapy, Colitis, Ulcerative surgery, Female, Follow-Up Studies, Humans, Infant, Male, Remission Induction, Retrospective Studies, Severity of Illness Index, Treatment Outcome, Glucocorticoids therapeutic use
- Abstract
Background: we aimed to analyze clinical and inflammatory markers of steroid non-response in patients with moderate/severe ulcerative colitis (UC) at the time of diagnosis., Methods: this study included patients who were graded as having moderate/severe UC and received corticosteroids as first-line therapy. Demographic, clinical and laboratory findings and pediatric ulcerative colitis activity scores (PUCAS) were recorded. Response to corticosteroids was assessed 30 days after the induction and long-term therapy., Results: twenty-eight children were diagnosed as having moderate/severe UC. Their mean age ± SD was 1 2.2 ± 4 years, and 17% were under 5 years of age. PUCAS at their initial admission was 56.9 ± 11.8. UC was observed at the left colon in 9 patients (32.1%), and pancolitis in 19 (67.9%). At the end of the 30th day, UC was completely remitted in 15 patients (53.5%), partially remitted in 2 (7.1%), and no response in 11 (39.2%). Short-term follow-up showed partial remission in 2 patients, and overall remission with steroid in 17 (60.7%). Non-responders were given second-line treatment; steroid dependency was documented in 2 patients (7.1%) and another 2 (7.1%) patients underwent colectomy. Predictors for steroid non-response were analyzed and only PUCAS at the initial admission was found to be associated with non-response to steroids (51.4 ± 11.4 vs. 65.4 ± 6.8, P<0.05)., Conclusions: approximately half of the pediatric patients had complete response to steroid therapy in a long period. PUCAS could be used as a potential marker of "failed response" to steroid, but should be supported with a number of prospective randomized controlled studies.
- Published
- 2011
- Full Text
- View/download PDF
31. A rare cause of refractory ascites in a child: familial Mediterranean fever.
- Author
-
Cakir M, Ozgenc F, Baran M, Arikan C, Sezak M, Tuncyurek M, Ergun O, and Yagci RV
- Subjects
- Ascites drug therapy, Ascites pathology, Child, Colchicine therapeutic use, Familial Mediterranean Fever drug therapy, Familial Mediterranean Fever pathology, Gout Suppressants therapeutic use, Humans, Male, Radiography, Abdominal, Radiography, Thoracic, Tomography, X-Ray Computed, Treatment Outcome, Ascites etiology, Familial Mediterranean Fever complications
- Abstract
Familial Mediterranean fever (FMF) is hereditary episodic febrile syndrome characterized by acute attacks of fever and serosal inflammation, generally lasting 1-3 days and resolves spontaneously. Apart from abdominal pain, patients may present with variety of abdominal manifestations such as acute peritonitis, mechanical intestinal obstruction, diarrhea, bowel infarction, amyloidosis and small amounts of peritoneal fluid during the acute attacks. A 6-year-old boy was admitted with massive ascites. After extensive laboratory investigations, no causative agent could be identified. On subsequent days, he developed fever and skin eruptions. Acute-phase reactants were increased. A second tomography revealed cystic fluid collection near the anterior side of spleen that invades the stomach. An exploratory was performed and histopathological examination of the all resected specimens revealed mix inflammatory cell infiltrate associated with severe myofibroblast proliferation suggesting chronic inflammatory process on the mesenteric region. A diagnosis of FMF was suspected based on the clinical, laboratory and histopathological findings, and a trial of colchicine therapy initiated. Ascites and other serosal inflammations improved within 1 week without any recurrence during the next 12-month period on colchicine treatment. Atypical presentations of FMF have been increasingly reported. Pediatricians should keep FMF in mind in the differential diagnosis of massive ascites especially in regions where hereditary inflammatory disease are common.
- Published
- 2010
- Full Text
- View/download PDF
32. Long-term effect of gluten-free diet on growth velocity in Turkish children with celiac disease.
- Author
-
Aydogdu S, Midyat L, Cakir M, Tumgor G, Yuksekkaya HA, Baran M, Arikan C, Ozgenc F, and Yagci RV
- Subjects
- Adolescent, Body Height, Body Weight, Child, Child, Preschool, Female, Humans, Male, Turkey, Celiac Disease physiopathology, Diet, Gluten-Free, Growth physiology
- Abstract
We sought to analyze the long-term growth in children with celiac disease (CD) as well as the association of height and weight SD score at the end of 4 years with the demographic and clinical presentation at initial admission. Thirty-four children with CD were enrolled in the study and followed for at least 4 years. Patients were divided into three groups (Group 1: patients
10 years, at the time of diagnosis). Patients' charts were reviewed for demographic and clinical features at initial admission. Anthropometric measurements at initial admission, at 6th months, and 1st, 2nd, 3rd, and 4th years were recorded. Gluten-free diet led to rapid increase in weight SD and height SD score in patients - Published
- 2009
- Full Text
- View/download PDF
33. A rare complication of central catheter in an infant with intestinal failure.
- Author
-
Cakir M, Levent E, Yuksekkaya HA, Ergun O, Ozgenc F, and Yagci RV
- Subjects
- Catheterization, Central Venous instrumentation, Equipment Failure, Humans, Infant, Male, Parenteral Nutrition, Catheterization, Central Venous adverse effects, Iatrogenic Disease, Short Bowel Syndrome physiopathology
- Abstract
Objective: To report the successful percutaneous transcatheter removal of a snapped intracardiac fragment of the central vein catheter in an infant., Clinical Presentation and Intervention: A 3-month-old infant with short bowel syndrome who required long-term parenteral nutrition via portacath central catheter was hospitalized. Two months after the insertion of the second catheter, the distal tip of the catheter snapped and became tangled in the heart. The catheter fragment was removed by a percutaneous femoral vein approach using a 10-mm diameter snare-loop catheter (Amplatz). The procedure was performed under fluoroscopy; the fragment was removed after being released into the right ventricle by pulling the proximal tip with a pigtail catheter. No complications were observed and the patient was transported back to the intensive unit in stable condition., Conclusion: Central catheter-related complications may cause difficulties in patients with short bowel syndrome prior to intestinal transplantation. The percutaneous retrieval of the fragmented catheter using a snare-loop catheter is a safe and reliable technique and may be used instead of surgery especially in small infants., ((c) 2008 S. Karger AG, Basel)
- Published
- 2008
- Full Text
- View/download PDF
34. Larengopharengeal reflux in patients with severe adeno-tonsil hyperplasia.
- Author
-
Tumgor G, Midilli R, Yuksekkaya HA, Cakir M, Ozgenc F, and Yagci RV
- Subjects
- Adolescent, Child, Child, Preschool, Female, Gastroesophageal Reflux diagnosis, Gastroesophageal Reflux physiopathology, Gastroesophageal Reflux therapy, Humans, Infant, Male, Otorhinolaryngologic Diseases physiopathology, Gastroesophageal Reflux complications, Otorhinolaryngologic Diseases etiology
- Published
- 2006
- Full Text
- View/download PDF
35. Positive association of macrophage migration inhibitory factor gene-173G/C polymorphism with biliary atresia.
- Author
-
Arikan C, Berdeli A, Ozgenc F, Tumgor G, Yagci RV, and Aydogdu S
- Subjects
- Analysis of Variance, Biliary Atresia enzymology, Biliary Atresia epidemiology, Biliary Atresia immunology, Biomarkers blood, Case-Control Studies, Confidence Intervals, Female, Genetic Predisposition to Disease, Genotype, Humans, Infant, Liver Diseases enzymology, Liver Diseases epidemiology, Liver Diseases immunology, Macrophage Migration-Inhibitory Factors blood, Male, Odds Ratio, Polymorphism, Restriction Fragment Length, Risk Factors, Severity of Illness Index, Biliary Atresia genetics, Gene Frequency, Liver Diseases genetics, Macrophage Migration-Inhibitory Factors genetics, Polymorphism, Genetic
- Abstract
Background: Macrophage migration inhibitory factor (MIF) is a pleiotrophic lymphocyte and macrophage cytokine; it is likely to play an important role in innate immunity. Its expression was increased in several inflammatory diseases, and MIF gene polymorphisms have an effect on disease outcome and response to glucocorticoid treatment., Aim: To investigate the role of the 173G/C polymorphism of the MIF gene for susceptibility to biliary atresia (BA)., Method: Between February 2002 and November 2004, 18 patients (mean age 1 +/- 0.4 years) diagnosed as having BA were studied. After informed consent, blood was collected, and DNA was obtained. MIF 173C/G polymorphism was detected using the polymerase chain reaction-restriction fragment length polymorphism based method. BA patients were compared with a group of chronic liver disease patients (CLD) (n = 36) and a group of unrelated healthy controls (n = 103)., Results: MIF-173C allele frequency was significantly higher than both the CLD and healthy control groups (P = 0.03, odds ratio [OR] 4.4, 95% confidence interval [CI] 1.3-15.1; P = 0.000, OR 4.1, 95% CI 2.3-7.6, respectively). Univariate analysis showed that MIF-173G/C polymorphism was significantly associated with BA (for GC genotype, OR = 6, 95 % CI 2.8-11.5, P = 0.000). There was no significant correlation between pediatric end stage liver disease score and MIF genotypes both in BA and CLD groups., Conclusion: Our results suggest that the -173C allele of the MIF gene might be associated with the susceptibility to BA.
- Published
- 2006
- Full Text
- View/download PDF
36. Trigonocephaly and Wilson's disease in two siblings.
- Author
-
Cogulu O, Onay H, Ozgenc F, Karaca E, Gunduz C, Tzetis M, Cankaya T, Kanavakis E, and Ozkinay F
- Subjects
- Abnormalities, Multiple genetics, Adenosine Triphosphatases genetics, Cation Transport Proteins genetics, Child, Child, Preschool, Copper-Transporting ATPases, DNA Mutational Analysis, Female, Humans, Male, Pedigree, Polymorphism, Genetic, Siblings, Syndrome, Abnormalities, Multiple pathology, Craniosynostoses pathology, Hepatolenticular Degeneration pathology
- Abstract
Trigonocephaly and Wilson's disease (WD) are two different entities. The former is a type of craniosynostosis that occurs because of fusion of the metopic suture and the latter, also called hepatolenticular degeneration, is caused by an accumulation of copper in tissues all over the body because of failure of copper excretion. No single gene has been identified for trigonocephaly whereas the ATP7B gene has been shown to be responsible for Wilson's disease. Here we present two siblings born to nonconsanguineous parents who both presented with trigonocephaly, Wilson's disease and facial dysmorphism. In addition, the female has renal agenesis and the male has a history of undescended testis. Karyotypes were normal and no mutation of the ATP7B gene has been identified in the patients or their parents.
- Published
- 2005
37. Impact of liver transplantation on renal function of patients with congenital hepatic fibrosis associated with autosomal recessive polycystic kidney disease.
- Author
-
Arikan C, Ozgenc F, Akman SA, Kilic M, Tokat Y, Yagci RV, and Aydogdu S
- Subjects
- Adolescent, Creatinine blood, Cyclosporine therapeutic use, Glomerular Filtration Rate, Humans, Immunosuppressive Agents therapeutic use, Polycystic Kidney, Autosomal Recessive epidemiology, Kidney physiopathology, Liver Cirrhosis congenital, Liver Cirrhosis surgery, Liver Transplantation physiology, Polycystic Kidney, Autosomal Recessive physiopathology
- Abstract
Congenital hepatic fibrosis (CHF) is an uncommon autosomal recessive malformation. It may be associated with extrahepatic manifestations such as polycystic kidney disease. The main consequence is portal hypertension and bleeding from varices. Despite liver transplantation as a therapeutic option for this patient, long-term impact of liver transplantation on renal functions of patients with autosomal recessive polycystic kidney disease with associated liver disease is not well known. In this study, we aimed to analyze the patient's renal function after liver transplantation by creatinine clearance, glomerular filtration rate, and renal resistive indexes. Between March 1997 and September 2002, three of 50 orthotopic liver transplantation (OLT) were performed because of CHF associated with ARPKD at Ege University Organ Transplantation and Research Center. Baseline immunosuppression consisted of prednisone and cyclosporine A (CSA). The mean follow-up of the patients was 2.1 yr. Blood urea and creatinine levels were decreased after operation in all patients and remained within the normal range at the sixth and 12th month, whereas the level of the third patient were increased at the 18th month. RRI values of patients were not found different at the sixth month whereas, RRI values of patients were decreased at the 12th month and remained unchanged at the 18th month of follow-up. During the study period hypertension developed in one patient at the 16th month and resolved with antihypertensive treatment and decreasing dosage of CSA. Kidney function has remained satisfactory in all of the patients despite the use of cyclosporine. OLT can provide good survival in patients with CHF associated with ARPKD.
- Published
- 2004
- Full Text
- View/download PDF
38. Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection.
- Author
-
Ozgenc F, Dikici B, Targan S, Doganci T, Akman S, Aydogdu S, and Yagci RV
- Subjects
- Administration, Oral, Alanine Transaminase blood, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Interferon alpha-2, Interferon-alpha administration & dosage, Interferon-alpha adverse effects, Lamivudine administration & dosage, Lamivudine adverse effects, Male, Recombinant Proteins, Time Factors, Treatment Outcome, Antiviral Agents therapeutic use, Hepatitis B, Chronic drug therapy, Interferon-alpha therapeutic use, Lamivudine therapeutic use
- Abstract
Aim: To compare additive efficacy of combination therapy including interferon (IFN)-alpha2a+lamivudine (3TC) to IFN-alpha2b+3TC in children with chronic hepatitis B virus (HBV) infection., Material and Methods: Chronic hepatitis B infection was determined by presence of HBsAg, HBeAg and HBV DNA in serum screened at 3 months intervals for at least 1 year, serum alanine transaminase (ALT) levels more than 1.5-times the upper normal limit and chronic hepatitis with histological activity index (HAI) more than 6 by liver biopsy. Sixty-three children with chronic hepatitis B infection were treated randomly with thrice-weekly subcutaneous injections of 5 MU/m2 recombinant IFN-alpha2a (n=29) or recombinant IFN-alpha2b (n=34) with the same dose, intervals for 6 months. Patients also received 3TC (4 mg/kg/day, max 100 mg/day) orally daily combined with IFN and continued for 12 months. End of therapy response was defined as ALT normalization, HBV DNA clearance and HBe/anti-HBe seroconversion. Breakthrough infection was determined as re-emergence of HBV DNA in serum after its clearance. Response rate, incidence of side effects and breakthrough infection were compared between IFN-alpha2a+3TC- and IFN-alpha2b+3TC-treated patients., Results: Response rate was 44.8% (n=13) with IFN-alpha2a+3TC and 47.1% (n=16) with IFN-alpha2b+3TC (P=1.0). No significant difference was found in respect to the DNA clearance (P=0.32), anti-HBe (P=1.0), anti-HBs (P=0.09) seroconversion and response rates (P=1.0) between the groups. Breakthrough infection was detected in 1 (3.4%) case on IFN-alpha2a and none of the cases on IFN-alpha2b (P=0.46). All of the patients experienced flu-like symptoms, malaise and fatigue; however, side effect interfering with therapy was not encountered., Conclusion: No significant difference was found in response rates achieved by combination therapies based on IFN-alpha2a and IFN-alpha2b. Clinical efficacy of 3TC and two different IFN subtypes was found similar.
- Published
- 2004
39. Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study.
- Author
-
Dikici B, Ozgenc F, Kalayci AG, Targan S, Ozkan T, Selimoglu A, Doganci T, Kansu A, Tosun S, Arslan N, Kasirga E, Bosnak M, Haspolat K, Buyukgebiz B, Aydogdu S, Girgin N, and Yagci RV
- Subjects
- Adolescent, Alanine Transaminase blood, Child, Child, Preschool, DNA, Viral analysis, Drug Administration Schedule, Drug Therapy, Combination, Female, Hepatitis B e Antigens blood, Hepatitis B virus isolation & purification, Hepatitis B, Chronic diagnosis, Hepatitis B, Chronic virology, Humans, Interferon alpha-2, Male, Recombinant Proteins, Antiviral Agents administration & dosage, Hepatitis B, Chronic drug therapy, Interferon-alpha administration & dosage, Lamivudine administration & dosage
- Abstract
Background and Aim: The aim of the present study was to compare the therapeutic efficacy of three different regimens in childhood chronic hepatitis B (CHB) infection., Methods: A total of 182 children with CHB infection were prospectively allocated to three random groups. Sixty-two patients in the first group received high-dose interferon (IFN)-alpha 2b (10 MU/m2) thrice/weekly alone for 6 months. In the second (n = 60) and third groups (n = 60), IFN-alpha was used for 6 months (5 MU/m2) thrice/weekly in combination with lamivudine (LAM) (4 mg/kg, maximum 100 mg/day) for 12 months. Lamivudine was started simultaneously with IFN in the second group, while it was started 2 months prior to IFN injections in the third group., Results: The initial mean alanine aminotransferase (ALT) values for the first, second and third groups were 109 +/- 93 IU/L, 101 +/- 64 IU/L and 92 +/- 42 IU/L, respectively (P > 0.05). At the end of the therapy, ALT values decreased to 82 +/- 111 IU/L, 38 +/- 41 IU/L and 29 +/- 16 IU/L in groups 1, 2 and 3, respectively. The mean ALT value of the first group was significantly different to the second and third groups (P = 0.046 and P = 0.002, respectively) at the end of the therapy and these differences were found to be sustained after 18 months. However, results in the second and third groups were similar (P > 0.05). There were no significant differences in HBeAg clearance and anti-HBe seroconversion at the initial stage, 12 months and 18 months between the three groups (P > 0.05). Hepatitis B virus (HBV) DNA clearance in the first group was different from the second and third groups, while the second and third groups had similar HBV DNA clearance ratios at 12 and 18 months. No significant difference was found in the complete response (normalization of ALT, clearance of HBV DNA and seroconversion of anti HBe) ratios of all groups (at 12 months: 28.8, 45.5, 35.8% and at 18 months 33.3, 49 and 34% in groups 1, 2 and 3, respectively, P > 0.05)., Conclusions: Although the ALT normalization and HBV DNA clearance ratios of IFN plus LAM combination groups were better than the high-dose IFN-alpha monotherapy group, no significant difference was found in the complete response ratios of all three groups.
- Published
- 2004
- Full Text
- View/download PDF
40. Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy.
- Author
-
Yalaz M, Aydogdu S, Ozgenc F, Akisu M, Kultursay N, and Yagci RV
- Subjects
- Chelating Agents therapeutic use, Female, Hepatolenticular Degeneration drug therapy, Humans, Infant, Newborn, Penicillamine therapeutic use, Pregnancy, Pregnancy Complications drug therapy, Chelating Agents adverse effects, Fetal Diseases chemically induced, Leukopenia chemically induced, Neutropenia chemically induced, Penicillamine adverse effects
- Abstract
Normal fertility is sustained by progress in the medical therapy of Wilson's disease; however, pregnancy complications are encountered more frequently. The mother we present is a Wilson's disease patient who had been compliant with D-penicillamine for the preceding 13 years. She was admitted with unplanned pregnancy at the 16th gestational week. The dose of D-penicillamine could be reduced to 600 mg/d related to the underlying disease. Pregnancy ended with premature labor and delivery at the 29-30th weeks. The baby experienced type I respiratory distress and was treated by surfactant and mechanical ventilation. Neutropenia and leucopenia were documented at 6th postnatal hours. The baby showed neutropenia and leucopenia for 5 days and resolving without any further therapy. Intrauterine D-penicillamine was suspected to cause transient neonatal myelosuppression.
- Published
- 2003
41. Celiac disease in children with Down syndrome: importance of follow-up and serologic screening.
- Author
-
Cogulu O, Ozkinay F, Gunduz C, Cankaya T, Aydogdu S, Ozgenc F, Kutukculer N, and Ozkinay C
- Subjects
- Adolescent, Autoantibodies blood, Celiac Disease epidemiology, Child, Child, Preschool, Female, Follow-Up Studies, Gliadin immunology, Humans, Immunoglobulin A blood, Incidence, Male, Celiac Disease blood, Celiac Disease complications, Down Syndrome blood, Down Syndrome complications
- Abstract
Background: Celiac disease, also known as gluten-sensitive enteropathy, is a chronic inflammation disease of the small intestinal mucosa. Detection of Ig-A antigliadin antibodies (AGA) and antiendomysial antibodies (EMA) in serum is important in the diagnosis and screening for celiac disease. Antiendomysial antibodies have greater sensitivity compared to antigliadin antibodies. It has been reported that the prevalence of celiac disease is higher in children with Down syndrome than the other autoimmune conditions. The aim of the present study was to investigate the incidence of celiac disease in children with Down syndrome, to assess the availability of Ig-A AGA and EMA for serologic screening, and to highlight the importance of follow-up for children with Down syndrome., Methods: Forty-seven children with Down syndrome without known celiac disease were tested for total blood count, thyroid function tests, immunoglobulin values, Ig-A AGA and EMA. Duodenal biopsy was performed on eight patients who showed at least one serologically positive marker., Results: The ages of the children with Down syndrome ranged from 2 to 18 years (30 boys/17 girls). The mean age was 6.55 +/- 3.88. Total blood count and immunoglobulin values were normal. Eleven of the 47 patients (23.40%) were found to be serologically positive, 10 (21.28%) having antigliadin antibody concentrations above normal; and six (12.77%) being positive for antiendomysial antibody. In five patients (10.64%), both Ig-A AGA and EMA concentrations were high and positive. Duodenal biopsies of three of eight cases (37.50%) revealed villous atrophy, lymphocyte infiltration and crypt hyperplasia. Three cases with abnormal biopsy results (100%) were below the 10th percentile for weight and height. Hypo-thyroidism was detected in one of 11 cases where at least one serologic marker was positive., Conclusion: Children with Down syndrome should be carefully examined in their follow up, and celiac disease should be considered in cases with growth retardation. Ig-A antigliadin antibodies and EMA are non-invasive, cheap and readily available serologic screening tests for celiac disease, and the positivity of both markers gives the most reliable result.
- Published
- 2003
- Full Text
- View/download PDF
42. Decreased ratio of CD4/CD8 lymphocytes might be predictive for successful interferon alpha and lamivudine combined therapy in childhood chronic hepatitis B infection: A preliminary study.
- Author
-
Genel F, Unal F, Ozgenc F, Aksu G, Aydogdu S, Kutukculer N, and Yagci RV
- Subjects
- Adolescent, Alanine Transaminase blood, Alanine Transaminase drug effects, Antigens, Differentiation, T-Lymphocyte drug effects, Antigens, Differentiation, T-Lymphocyte metabolism, Aspartate Aminotransferases drug effects, Biomarkers blood, Cell Adhesion Molecules drug effects, Child, Child Welfare, Child, Preschool, Drug Therapy, Combination, Female, Follow-Up Studies, Hepatitis B e Antigens blood, Hepatitis B e Antigens drug effects, Humans, Immunoglobulin A blood, Immunoglobulin A drug effects, Immunoglobulin G blood, Immunoglobulin G drug effects, Infant, Infant Welfare, Male, Predictive Value of Tests, Prospective Studies, T-Lymphocyte Subsets drug effects, Treatment Outcome, Antiviral Agents therapeutic use, CD4-Positive T-Lymphocytes drug effects, CD4-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes drug effects, CD8-Positive T-Lymphocytes metabolism, Hepatitis B, Chronic drug therapy, Interferon-alpha therapeutic use, Lamivudine therapeutic use, Reverse Transcriptase Inhibitors therapeutic use
- Abstract
Background: In the development of chronic hepatitis with hepatitis B virus infection and in response to therapy, the immune status of the infected host plays a critical role. In this study, immunological variables were assessed in patients before interferon alpha and lamivudine therapy to determine if any pretreatment immunological parameter could be an indicator of response to therapy in childhood chronic hepatitis B infection., Methods: Forty-four patients with chronic hepatitis B virus infection, aged 9.0 +/- 3.9 years, were enrolled in the study. The pretreatment clinical features, biochemical test results, histological activity indexes and immunological parameters were evaluated. All patients received interferon alpha for 6 months and lamivudine for 52 weeks. Four patients who could not be followed up were excluded from the study. The other 40 patients have been followed for a mean period of 27.5 +/- 9.7 months after therapy discontinuation., Results: Seventeen patients showed loss of hepatitis B early antigen (HBeAg) with appearance of anti-HBe (42.5%) and six of those who responded also showed loss of hepatitis B surface antigen (HBsAg) with the presence of anti-HBs (15%). Except elevated aspartate aminotransferase levels, there was no significantly correlation between response and sex, age, pretreatment duration of disease and histological activity indexes. Pretreatment immunoglobulins (Ig), IgG subclasses, complement C3, C4 and secretory IgA levels were also not found to be significantly related to response. The evaluation of lymphocyte subsets showed that therapy responders had significantly reduced pretreatment ratios of CD4/CD8+ lymphocytes due to prominent increased percentages of CD8+ cells. The other cellular immunity parameters and some cell surface adhesion molecules were similar in both groups., Conclusion: This study emphasizes the importance of increased pretreatment CD8+ lymphocyte percentages leading to a significant decrease in CD4/CD8 ratio in chronic hepatitis B virus infection of childhood as an immunological factor predicting response to treatment.
- Published
- 2003
- Full Text
- View/download PDF
43. Treatment of Helicobacter pylori gastritis improves dyspeptic symptoms in Turkish children.
- Author
-
Ozgenc F, Akman SA, Arikan C, Alkanat MB, Aydogdu S, and Yagci RV
- Subjects
- Adolescent, Anti-Bacterial Agents therapeutic use, Child, Child, Preschool, Gastritis drug therapy, Humans, Omeprazole therapeutic use, Gastritis microbiology, Helicobacter Infections drug therapy, Helicobacter pylori
- Published
- 2003
- Full Text
- View/download PDF
44. Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection.
- Author
-
Dikici B, Kalayci AG, Ozgenc F, Bosnak M, Davutoglu M, Ece A, Ozkan T, Ozeke T, Yagci RV, and Haspolat K
- Subjects
- Adolescent, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Immunization Schedule, Immunocompetence physiology, Immunotherapy, Active adverse effects, Liver Cirrhosis prevention & control, Liver Function Tests, Male, Probability, Reference Values, Risk Assessment, Severity of Illness Index, Statistics, Nonparametric, Treatment Outcome, Turkey, Hepatitis B Vaccines therapeutic use, Hepatitis B, Chronic immunology, Hepatitis B, Chronic therapy, Immunotherapy, Active methods
- Abstract
Aim: Hepatitis B virus (HBV) infection is a major global health concern and is the most common cause of chronic liver disease worldwide. Our aim was to investigate the efficacy of specific HBV vaccination as active immunotherapy in treating chronic hepatitis B (CHB) infection during the immunotolerant phase of children with normal aminotransferase values and high viral load., Materials and Methods: Seventy-four patients never vaccinated before were randomly and prospectively recruited into two groups. Group 1 included 43 patients vaccinated with three standard injections of the GenHevac B vaccine at 30-day intervals. Group 2 contained 31 patients who did not receive any medication or vaccination (control group). Postvaccination serologic and virologic evaluation was performed 6 months after the first injection and at the end of the 12th month. Response to therapy was defined as loss of HBV DNA in serum and hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg), development of hepatitis B e antibody (anti-HBe)., Results: The mean baseline alanine aminotransferase (ALT) value in Group 1 was 33.0 +/- 9.6 IU/l, 34.6 +/- 13.9 IU/l at 6 months after first injection and 34.3 +/- 17.1 IU/l at end of 12 months (P > 0.05). In Group 1 the HBV DNA load at the start of immunization was 3571 +/- 1292 pg/ml; this value was 3220 +/- 1217 pg/ml at the 6th month and 2931 +/- 1292 pg/ml at the 12th month (P > 0.05). In Group 2 the mean ALT values at the beginning of therapy and at the 6th and 12th months were 32.6 +/- 7.8, 32.3 +/- 8.0 and 30.3 +/- 7.3 IU/l, respectively (P > 0.05), and the mean viral load HBV DNA values were 3909 +/- 1378, 3546 +/- 869 and 3106 +/- 718 pg/ml, respectively (P > 0.05). There was no statistically significant difference between Group 1 and Group 2 at the end of the 6th and 12th months in the mean ALT values and mean viral load of HBV DNA (P > 0.05). Except for one patient in each group, hepatitis B surface antigen and HBeAg clearance or hepatitis B surface antibody and anti-HBe seroconversion were not observed during follow-up (P > 0.05)., Conclusion: In this multicentered study comparison of vaccinated and unvaccinated groups of immunotolerant children with CHB infection showed no difference in the clearance of HBV DNA or seroconversion from HBeAg to anti-HBe. Different immunization protocols should be considered for future investigations in the immunotolerant phase of children with CHB infection.
- Published
- 2003
- Full Text
- View/download PDF
45. Immune status and autoantibody formation in children with chronic hepatitis B infection.
- Author
-
Unal F, Genel F, Ozgenc F, Aksu G, Aydogdu S, Kutukculer N, and Yagci RV
- Subjects
- Adolescent, Antibody Formation, Child, Child, Preschool, Female, Humans, Infant, Male, Autoantibodies biosynthesis, Hepatitis B, Chronic immunology, Immune System physiopathology
- Abstract
Background: The hepatitis B virus (HBV) causes a wide spectrum of disease which ranges from acute hepatitis to liver cirrhosis. Patients who fail to mount a vigorous immune response in acute HBV develop chronic infection. Therefore, the aim of the study was to determine the cellular and humoral immune parameters of the patients with chronic HBV and to evaluate the prevalence of autoantibodies before the beginning of immunomodulator and antiviral therapy., Methods: In this comparative study, serum immunoglobulins, IgG subclasses, secretory IgA, serum complement components, lymphocyte subsets and CD11a, CD18, CD54 molecules on lymphocytes were determined in 44 hospitalized patients of chronic HBV infection and 20 cases of healthy control subjects., Results: Significant increase in IgG and significant decrease in the complement C4 were observed. The mean percentage of CD3+ lymphocytes, reflecting the percentage of total T cells was significantly higher in the patient group due to the increase of CD8+ lymphocytes. The mean percentage of CD19+ B lymphocytes was lower in the patient group secondary to the increase of their total T cells. No significant difference was found in cell surface adhesion molecules between patient and control groups. The percentage of antinuclear antibody positivity was 18.2%., Conclusions: Our data show that ANA formation is part of the natural course of chronic HBV infection and this value may reflect the tendency to autoimmune diseases and the importance of clinical follow-up. The abnormalities observed in immunological parameters may reflect the role of the cellular and humoral immune system in pathogenesis.
- Published
- 2002
46. Inflammatory myofibroblastic tumor of small bowel wall in childhood: Report of a case and a review of the literature.
- Author
-
Demirkan NC, Akalin T, Yilmaz F, Ozgenc F, Ozcan C, Alkanat MB, and Aydogdu S
- Subjects
- Child, Preschool, Female, Granuloma, Plasma Cell surgery, Humans, Intestinal Diseases surgery, Intestinal Obstruction etiology, Intestinal Obstruction pathology, Granuloma, Plasma Cell pathology, Intestinal Diseases pathology, Jejunum pathology
- Abstract
Benign intestinal tumors are rare in children, however we describe an inflammatory myofibroblastic tumor (IMT) of the jejunum in a 2-year-old girl who presented with an intestinal obstruction. During laparotomy, an annular mass around the jejunum was resected, from which a histological diagnosis of IMT was made. A review of the literature for this rare entity emphasizes the importance of histological confirmation of its benign nature. Because of the risk of local recurrence, IMT cases should have a long-term follow up.
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.